Deep Longevity launches its MindAge psychological aging clock to the wider world – building on the data of over 250,000 people who have already used it to determine their psychological pace of aging.
Hong Kong-based Deep Longevity, which is wholly owned by Endurance RP Ltd, is developing explainable AI systems to track the rate of aging at the molecular, cellular, tissue, organ, system and physiological levels. Now it has psychological aging in its sights as well.
Longevity.Technology: Mens sana in corpore sano – Juvenal would have approved of Deep Longevity’s take on lifespan, healthspan and wellness. When it comes to tracking, measuring and attempting to twiddle the dials of aging, Deep Longevity’s range of clocks covers all the bases, and it is good to see mental health afforded equal footing. The idea that true longevity can only be achieved through improving both physical and mental wellbeing has taken off, with investor Christian Angermayer announcing a $120 million fund focused on mental health ventures and iamYiam scaling up its workforce wellbeing platform.
Deep Longevity has been developing a broad range of biomarkers of aging to maintain physical health and wellness, restore youthfulness and improve mental health and wellbeing. To that end, it has launched its MindAge© psychological aging clock.
The MindAge tests are now available via the Deep Longevity website and via the Young.AI iPhone app available in the Apple Appstore. It builds on the recently published paper PsychoAge and SubjAge: Development of Deep Biomarkers of Psychological
and Subjective Age Using Artificial Intelligence.
Deep Longevity also announced the formation of a Scientific Advisory Board (SAB) comprised of certain experts in longevity biotechnology. Chaired by Alex Zhavoronkov, PhD, the Chief Longevity Officer of Deep Longevity, the SAB will help direct and review the company’s work in the development and applications of deep biomarkers of human aging.
Deep Longevity’s SAB is a longevity Who’s Who, including Dr Eric Verdin (CEO of the Buck Institute for Research on Aging), Dr Daniel Kraft (Stanford & Harvard trained physician-scientist, Founder of Exponential Medicine, Chair of XPrize Pandemic Alliance Task force), Dr Morten Scheibye-Knudsen (head of the Biology of Aging Laboratory and professor at the University of Copenhagen), Dr Vadim Gladyshev (Head of the Gladyshev Laboratory at Harvard University) and Dr Wei-Wu He (Chairman of Human Longevity, Inc).
Among the board, Deep Longevity executed two Consulting Agreements with recognised leaders in the fields of longevity biotechnology and longevity medicine, Drs Verdin and Gladyshev in respect of the provision of scientific and business advisory services to Deep Longevity. They will receive an award of 1,670,000 and 1,110,000 Consultant Shares, respectively, which shares will be subject to certain vesting conditions.
Jim Mellon, Chairman of the board of directors of Endurance Longevity commented: “The scientific advisors of Deep Longevity are some of the highest-impact scientists, medical doctors, and most well-known experts in longevity. Under their leadership and supervision, the company will continue developing and commercializing the biological and psychological aging clocks and engaging in research with the academic and medical institutions as well as with the insurance companies worldwide”.
Alex Zhavoronkov, founder and Chief Longevity Officer, of Deep Longevity said: “Productive longevity is the most important asset we have in this life and Deep Longevity is dedicated to the measurement of aging at every level from biological to psychological. I am very happy to see the company expanding into the psychology of aging as it impacts our physical and mental health and well-being and is one of the areas we can control and intervene in.”